Publication: Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines.
| dc.contributor.author | Valiente, Manuel | |
| dc.contributor.author | Van Swearingen, Amanda E D | |
| dc.contributor.author | Anders, Carey K | |
| dc.contributor.author | Bairoch, Amos | |
| dc.contributor.author | Boire, Adrienne | |
| dc.contributor.author | Bos, Paula D | |
| dc.contributor.author | Cittelly, Diana M | |
| dc.contributor.author | Erez, Neta | |
| dc.contributor.author | Ferraro, Gino B | |
| dc.contributor.author | Fukumura, Dai | |
| dc.contributor.author | Gril, Brunilde | |
| dc.contributor.author | Herlyn, Meenhard | |
| dc.contributor.author | Holmen, Sheri L | |
| dc.contributor.author | Jain, Rakesh K | |
| dc.contributor.author | Joyce, Johanna A | |
| dc.contributor.author | Lorger, Mihaela | |
| dc.contributor.author | Massague, Joan | |
| dc.contributor.author | Neman, Josh | |
| dc.contributor.author | Sibson, Nicola R | |
| dc.contributor.author | Steeg, Patricia S | |
| dc.contributor.author | Thorsen, Frits | |
| dc.contributor.author | Young, Leonie S | |
| dc.contributor.author | Varešlija, Damir | |
| dc.contributor.author | Vultur, Adina | |
| dc.contributor.author | Weis-Garcia, Frances | |
| dc.contributor.author | Winkler, Frank | |
| dc.contributor.funder | MINISTERIO DE CIENCIA Y COMPETITIVIDAD | |
| dc.contributor.funder | Bristol-Myers Squibb | |
| dc.contributor.funder | Fundacion Ramon Areces | |
| dc.contributor.funder | Worldwide Cancer Research | |
| dc.contributor.funder | ASOCIACION ESPAÑOLA CONTRA EL CANCER | |
| dc.contributor.funder | Susan G. Komen Breast Cancer Foundation | |
| dc.contributor.funder | United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Cancer Institute (NCI) | |
| dc.contributor.funder | Cancer Research UK | |
| dc.contributor.funder | Brain Tumor Biorepository at the University of Colorado | |
| dc.contributor.funder | Melanoma Research Alliance | |
| dc.date.accessioned | 2024-12-10T09:09:45Z | |
| dc.date.available | 2024-12-10T09:09:45Z | |
| dc.date.issued | 2020-10-15 | |
| dc.description.abstract | Spread of cancer to the brain remains an unmet clinical need in spite of the increasing number of cases among patients with lung, breast cancer, and melanoma most notably. Although research on brain metastasis was considered a minor aspect in the past due to its untreatable nature and invariable lethality, nowadays, limited but encouraging examples have questioned this statement, making it more attractive for basic and clinical researchers. Evidences of its own biological identity (i.e., specific microenvironment) and particular therapeutic requirements (i.e., presence of blood-brain barrier, blood-tumor barrier, molecular differences with the primary tumor) are thought to be critical aspects that must be functionally exploited using preclinical models. We present the coordinated effort of 19 laboratories to compile comprehensive information related to brain metastasis experimental models. Each laboratory has provided details on the cancer cell lines they have generated or characterized as being capable of forming metastatic colonies in the brain, as well as principle methodologies of brain metastasis research. The Brain Metastasis Cell Lines Panel (BrMPanel) represents the first of its class and includes information about the cell line, how tropism to the brain was established, and the behavior of each model . These and other aspects described are intended to assist investigators in choosing the most suitable cell line for research on brain metastasis. The main goal of this effort is to facilitate research on this unmet clinical need, to improve models through a collaborative environment, and to promote the exchange of information on these valuable resources. | |
| dc.description.peerreviewed | Sí | |
| dc.description.tableofcontents | The authors want to thank the IT personnel from CNIO Marcos de Miguel and Jose Luis Fernandez for developing the BrMPanel webpage. Authors also want to thank the support from MINECO grants MINECO-Retos SAF2017-89643-R (to M. Valiente), Bristol-Myers Squibb-Melanoma Research Alliance Young Investigator Award 2017 (498103 to M. Valiente), Fundacion Ramon Areces (CIVP19S8163 to M. Valiente), Worldwide Cancer Research (19-0177 to M. Valiente), H2020-FETOPEN (828972 to M. Valiente), Clinic and Laboratory Integration Program CRI Award 2018 (54545 to M. Valiente), AECC Coordinated Translational Groups 2017 (GCTRA16015SEOA to M. Valiente), LAB AECC 2019 (LABAE19002VALI to M. Valiente), METAvivor Inc. (to P.D. Bos), SusanGKomen Career Catalyst Grant (CCR18548205 to P.D. Bos), Susan G Komen Career Catalyst Grant (CCR15332673 to J. Neman), NIH/NCI (1R01CA223544-01A1 to J. Neman), Department of Defense BCRP (BC141728 to J. Neman), Cancer Research UK (C5255/A15935 to N.R. Sibson), R37 CA227984 (to D.M. Cittelly), DoD BCRP BC141980 (to D.M. Cittelly), Metavivor Research Foundation (to D.M. Cittelly), in collaboration with the Brain Tumor Biorepository at the University of Colorado, PO1 CA114046 (to M. Herlyn and A. Vultur), and the Dr. Miriam and Sheldon G. Adelson Medical Research (to M. Herlyn), Harvard Ludwig Center, MIT/HMS Bridge grant (to R.K. Jain), the National Cancer Institute Outstanding Investigator Award (R35CA197743 to R.K. Jain), Susan G. Komen Foundation (PDF15331878 to G.B. Ferraro), Breast Cancer Research Foundation (to J.A. Joyce), Cancer Research UK iMAXT Consortium (to J.A. Joyce), Ludwig Institute for Cancer Research (to J.A. Joyce), Swiss Cancer League and the Swiss Bridge Award (to J.A. Joyce), NCI (R01CA121118 to S.L. Holmen), Melanoma Research Alliance (347651 to S.L. Holmen). M. Valiente is a Ramon y Cajal Investigator (RYC-2013-13365) and EMBO YIP (4053). | |
| dc.format.number | 20 | |
| dc.format.page | 4314-4323 | |
| dc.format.volume | 80 | |
| dc.identifier.citation | Cancer Res . 2020 Oct 15;80(20):4314-4323. | |
| dc.identifier.journal | Cancer Research | |
| dc.identifier.pmc | https://pmc.ncbi.nlm.nih.gov/articles/PMC7572582/pdf/nihms-1610523.pdf | |
| dc.identifier.pubmedID | 32641416 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/25870 | |
| dc.language.iso | eng | |
| dc.publisher | AMER ASSOC CANCER RESEARCH | |
| dc.relation.publisherversion | http://doi.org.10.1158/0008-5472.CAN-20-0291. | |
| dc.repisalud.institucion | CNIO | |
| dc.repisalud.orgCNIO | CNIO::Grupos de investigación::Grupo de Metástasis Cerebral | |
| dc.rights.accessRights | open access | |
| dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 International | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | BREAST-CANCER CELLS | |
| dc.subject | TUMOR BARRIER PERMEABILITY | |
| dc.subject | PATIENT-DERIVED XENOGRAFTS | |
| dc.subject | LUNG-CANCER | |
| dc.subject | RADIATION-THERAPY | |
| dc.subject | OPEN-LABEL | |
| dc.subject | MOUSE MODEL | |
| dc.subject | MELANOMA | |
| dc.subject | EFFICACY | |
| dc.subject | SURVIVAL | |
| dc.title | Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 9ff41ae3-2484-4d1c-bfb4-9f7a64487317 | |
| relation.isAuthorOfPublication.latestForDiscovery | 9ff41ae3-2484-4d1c-bfb4-9f7a64487317 |


